London-listed has reshuffled its current agreement with concerning its Chiadzwa Community Diamond Concession.
As previously announced in October 2018, the two parties formed an agreement for the development of Vast's Heritage concessions in the Marange Diamond Fields of Zimbabwe.
To manage and hold the interests of Vast Resources and Katanga Mining (pvt) Ltd, a joint venture company for the Chiadzwa Community, a new company, ‘Newco’, has been formed.
Consultancy partner, Botswana Diamonds will now receive new shares representing 2.5% of Newco, and Vast a total 97.5%, in the special purpose vehicle created by Vast.
Under the agreement, Botswana Diamonds will provide its consultancy efforts to Vast pro bono immediately for a five-year period whilst Vast will cover all capital requirements for up to $10 million.
Both companies explained how a review of an agreement between the two parties was required in light of Vast nearing its finalisation of an agreement with the Central Authorities on a package of ground in the Chiadzwa / Marange area.
Shares in Botswana Diamonds were trading 8.82% higher at 0.925p on Thursday morning.
Andrew Prelea, Chief Executive of VAST explained how the group concluded that BOD’s contribution as a consultant would ultimately “add significant value to the project.”
“We look forward to the diamond agreement being concluded and to work starting on what is highly prospective ground,” added Chairman of Botswana Diamonds, John Teeling.
Teeling further acknowledged Zimbabwe as a country “rich in resources” with “significant diamond potential” that is opening up to investment.
According to Reuters, President Emmerson Mnangagwa has recently tightened efforts to benefit from the region’s mineral resources to combat inflation and unemployment affecting Zimbabwe’s economy.
Vast is developing the project through Katanga Mining, a joint venture formed together with the local community at Chiadzwa, whom the company emphasised in its September update will directly benefit from natural resources acquired from the area.
Follow News & Updates from Vast Resources:and Botswana Diamonds:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Majid Shafiq, CEO of i3 Energy (AIM:I3E), and CFO, Graham Heath, discuss today’s follow-on deal to sell the Gain assets to Harvard Resources which will occur following the completion of the group’s previously announced C$80 million reverse takeover .
i3 Energy plc, an independent oil and gas company with assets and operations in the UK, Final Results for the year ended 31 December 2019 show significant operational progress for the pre-revenue company with net loss of £10.8m. To fund the Gain acquisition announced post period end in 2020, i3 is proposing to raise £30 million at a price of 5 pence per share, an 18% discount to the closing mid-price at which i3's shares suspended on 23 June 2020.
Oilex, the Operator of the PSC and on behalf of the JDPA joint venture, has reached amicable settlement with JPDA in East Timor with a settlement of US$0.8m payable in 2021 and 2022 financial years. The settlement amount is fully provided for in the FY19 accounts.
Avacta Group has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing in conjunction with Cytiva.
Shield Therapeutics said a reanalysis of the AEGIS-H2H study for its iron deficiency lead product Feraccru®/Accrufer® has confirmed the product as a credible alternative to IV therapy for patients with iron deficiency anaemia.